Literature DB >> 15240426

Gene transfer of inducible nitric oxide synthase complementary DNA regresses the fibrotic plaque in an animal model of Peyronie's disease.

Hugo H Davila1, Thomas R Magee, Dolores Vernet, Jacob Rajfer, Nestor F Gonzalez-Cadavid.   

Abstract

The goal of the present study was to investigate the antifibrotic role of inducible nitric oxide synthase (iNOS) in Peyronie's disease (PD) by determining whether a plasmid expressing iNOS (piNOS) injected into a PD-like plaque can induce regression of the plaque. A PD-like plaque was induced with fibrin in the penile tunica albuginea of mice and then injected with a luciferase-expressing plasmid (pLuc), either alone or with piNOS, following luciferase expression in vivo by bioluminescence imaging. Rats were treated with either piNOS, an empty control plasmid (pC), or saline. Other groups were treated with pC or piNOS, in the absence of fibrin. Tissue sections were stained for collagen, transforming growth factor (TGF) beta1, and plasminogen-activator inhibitor (PAI-1) as profibrotic factors; copper-zinc superoxide dismutase (CuZn SOD) as scavenger of reactive oxygen species (ROS); and nitrotyrosine to detect nitric oxide reaction with ROS. Quantitative image analysis was applied. Both iNOS and xanthine oxido-reductase (XOR; oxidative stress) were estimated by Western blot analysis. Luciferase reporter expression was restricted to the penis, peaked at 3 days after injection, but continued for at least 3 wk. In rats receiving piNOS, iNOS expression also peaked at 3 days, but expression decreased at the end of treatment, when a considerable reduction of plaque size occurred. Protein nitrotyrosine, XOR, and CuZn SOD increased, and TGFbeta1 and PAI-1 decreased. The piNOS gene transfer regressed the PD plaque and expression of profibrotic factors, supporting the view that endogenous iNOS induction in PD is defense mechanism by the tissue against fibrosis.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15240426     DOI: 10.1095/biolreprod.104.030833

Source DB:  PubMed          Journal:  Biol Reprod        ISSN: 0006-3363            Impact factor:   4.285


  20 in total

Review 1.  Cavernous smooth muscles: innovative potential therapies are promising for an unrevealed clinical diagnosis.

Authors:  Ahmed Mohamed Hassanin; Ahmed Zain Abdel-Hamid
Journal:  Int Urol Nephrol       Date:  2019-10-15       Impact factor: 2.370

Review 2.  Treatment of Peyronie's disease with PDE5 inhibitors: an antifibrotic strategy.

Authors:  Nestor F Gonzalez-Cadavid; Jacob Rajfer
Journal:  Nat Rev Urol       Date:  2010-03-09       Impact factor: 14.432

3.  The application of wrapping ureter by a pedicled gastrocolic omentum flap combined with an artificial external scaffold to prevent stoma stenosis in rabbit after ureterocutaneostomy.

Authors:  Shigeng Zhang; Fei Gao; Chong Xue; Nan Zhang; Feng Gao; Shaojiang Li; Jiaming Wen
Journal:  Int Urol Nephrol       Date:  2016-12-16       Impact factor: 2.370

4.  Amelioration of diabetes-induced cavernosal fibrosis by antioxidant and anti-transforming growth factor-β1 therapies in inducible nitric oxide synthase-deficient mice.

Authors:  Monica G Ferrini; Joanne Moon; Steve Rivera; Jacob Rajfer; Nestor F Gonzalez-Cadavid
Journal:  BJU Int       Date:  2011-08-18       Impact factor: 5.588

Review 5.  Pharmacological Management of Peyronie's Disease.

Authors:  Landon W Trost; Serap Gur; Wayne J G Hellstrom
Journal:  Drugs       Date:  2007       Impact factor: 9.546

6.  The transcriptional signatures of cells from the human Peyronie's disease plaque and the ability of these cells to generate a plaque in a rat model suggest potential therapeutic targets.

Authors:  Robert A Gelfand; Dolores Vernet; Istvan Kovanecz; Jacob Rajfer; Nestor F Gonzalez-Cadavid
Journal:  J Sex Med       Date:  2014-12-11       Impact factor: 3.802

7.  Treatment with a combination of ginger, L-citrulline, muira puama and Paullinia cupana can reverse the progression of corporal smooth muscle loss, fibrosis and veno-occlusive dysfunction in the aging rat.

Authors:  Monica G Ferrini; Su M Hlaing; Andre Chan; Jorge N Artaza
Journal:  Andrology (Los Angel)       Date:  2015-05-25

8.  Increased adenosine contributes to penile fibrosis, a dangerous feature of priapism, via A2B adenosine receptor signaling.

Authors:  Jiaming Wen; Xianzhen Jiang; Yingbo Dai; Yujin Zhang; Yuxin Tang; Hong Sun; Tiejuan Mi; Prasad V Phatarpekar; Rodney E Kellems; Michael R Blackburn; Yang Xia
Journal:  FASEB J       Date:  2009-10-26       Impact factor: 5.191

9.  Expression profiles for macrophage alternative activation genes in AD and in mouse models of AD.

Authors:  Carol A Colton; Ryan T Mott; Hayley Sharpe; Qing Xu; William E Van Nostrand; Michael P Vitek
Journal:  J Neuroinflammation       Date:  2006-09-27       Impact factor: 8.322

Review 10.  New discoveries in the basic science understanding of Peyronie's disease.

Authors:  Mark Jalkut; Nestor Gonzalez-Cadavid; Jacob Rajfer
Journal:  Curr Urol Rep       Date:  2004-12       Impact factor: 2.862

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.